Carl Domino Inc Has $1.06 Million Holdings in Gilead Sciences, Inc. (GILD)
Carl Domino Inc decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,124 shares of the biopharmaceutical company’s stock after selling 695 shares during the quarter. Carl Domino Inc’s holdings in Gilead Sciences were worth $1,063,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. FMR LLC increased its holdings in Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares during the period. Vanguard Group Inc. increased its holdings in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the period. Northern Trust Corp increased its holdings in Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after buying an additional 116,780 shares during the period. Toronto Dominion Bank increased its holdings in Gilead Sciences by 19.0% in the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after buying an additional 75,364 shares during the period. Finally, Fagan Associates Inc. increased its holdings in Gilead Sciences by 2.6% in the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 845 shares during the period. Institutional investors and hedge funds own 75.95% of the company’s stock.
Several equities analysts have commented on the stock. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a report on Wednesday. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $79.02 to $96.00 in a report on Tuesday. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have assigned a buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $85.53.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the sale, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The disclosure for this sale can be found here. Insiders have sold a total of 491,666 shares of company stock worth $36,442,567 over the last three months. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $81.74 on Thursday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market cap of $106,750.00, a P/E ratio of 9.30, a price-to-earnings-growth ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the firm posted $2.75 EPS. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. equities analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.